Barclays Maintains Overweight on CVS Health, Raises Price Target to $101

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Barclays analyst Andrew Mok maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $93 to $101.